{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-23-000172","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.761710+00:00","generated_at":"2026-06-08T02:41:27.624424+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GRI Bio reports Q3 net loss $11M; cash $3.5M; IPF trial on track","bullets":["Net loss $11.0M for 9 months ended Sep 30, 2023; R&D expenses $2.2M (vs $0.2M YoY) and G&A $7.2M (vs $0.4M YoY).","Cash and equivalents $3.5M as of Sep 30, 2023.","Phase 2a biomarker study of GRI-0621 for IPF on track to start before year-end 2023; interim data expected H1 2024.","GRI-0803 SLE program on track for IND filing H1 2024; Phase 1a SAD topline data expected Q3 2024.","Entered asset purchase agreement with Aardvark Therapeutics to sell legacy ADAIR assets and IP (no financial terms disclosed)."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-23-000172","json":"https://secwatch.observer/filing/0001824293-23-000172.json","markdown":"https://secwatch.observer/filing/0001824293-23-000172.md","text":"https://secwatch.observer/filing/0001824293-23-000172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000172/0001824293-23-000172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000172/val-20231115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:41:27.624424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7702cba619b781ffa567f61437f32662d0fd6dd","claim":"GRI Bio, Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $11.0 million for the nine months ended September 30, 2023.","evidence_excerpt":"GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2023, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000172/0001824293-23-000172-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $11.0 million for the nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}